Get the Stockscreener App
0.52
0.39%
0.002
After Hours:
.52
Altamira Therapeutics Ltd stock is traded at $0.52, with a volume of 68,711.
It is up +0.39% in the last 24 hours and down -21.13% over the past month.
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
See More
Previous Close:
$0.518
Open:
$0.4836
24h Volume:
68,711
Relative Volume:
0.19
Market Cap:
$1.96M
Revenue:
$132.70K
Net Income/Loss:
$-25.04M
P/E Ratio:
-0.0252
EPS:
-20.6616
Net Cash Flow:
-
1W Performance:
+4.27%
1M Performance:
-21.13%
6M Performance:
-68.29%
1Y Performance:
-82.67%
1-Day Range:
$0.4836
$0.525
1-Week Range:
$0.4701
$0.5418
52-Week Range:
$0.45
$17.20
Altamira Therapeutics Ltd Stock (CYTO) Company Profile
Name
Altamira Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Altamira Therapeutics Ltd Stock (CYTO) Latest News
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne
Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India
Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times
Altamira Therapeutics Faces Nasdaq Delisting - TipRanks
Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa
CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa
Altamira Medica obtains extended ISO 13485 certification - Investing.com
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan
Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia
Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey
Altamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ... By GuruFocus - Investing.com Canada
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics - Digital More
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics announces $4 million public offering - Investing.com India
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio - GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia - StockTitan
Trending tickers: latest investor updates on Microsoft, Bitcoin, Altamira and Ashtead - Yahoo Finance UK
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - GlobeNewswire
REPEAT — Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) - ForexTV.com
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark - Marketscreener.com
Altamira expands Bentrio distribution to Scandinavia - Investing.com
Altamira Therapeutics Announces Extension of Bentrio - GlobeNewswire
Altamira Therapeutics Ltd Stock (CYTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):